CY1121625T1 - Αναστολεις prmt5 και χρησεις αυτων - Google Patents
Αναστολεις prmt5 και χρησεις αυτωνInfo
- Publication number
- CY1121625T1 CY1121625T1 CY20181101294T CY181101294T CY1121625T1 CY 1121625 T1 CY1121625 T1 CY 1121625T1 CY 20181101294 T CY20181101294 T CY 20181101294T CY 181101294 T CY181101294 T CY 181101294T CY 1121625 T1 CY1121625 T1 CY 1121625T1
- Authority
- CY
- Cyprus
- Prior art keywords
- compounds
- prmt5
- prmt5 inhibitors
- treat
- useful
- Prior art date
Links
- 102100034607 Protein arginine N-methyltransferase 5 Human genes 0.000 title abstract 3
- 101710084427 Protein arginine N-methyltransferase 5 Proteins 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 230000000694 effects Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
- C12N9/1007—Methyltransferases (general) (2.1.1.)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Obesity (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Στο παρόν περιγράφονται ενώσεις του Τύπου (Α), φαρμακευτικά αποδεκτά άλατα αυτών, και φαρμακευτικές συνθέσεις αυτών. Οι ενώσεις της παρούσας εφεύρεσης είναι χρήσιμες για την αναστολή της δράσης PRMT5. Περιγράφονται επίσης μέθοδοι χρήσης των ενώσεων για τη θεραπεία των προκαλούμενων από PRMT5 διαταραχών.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261745485P | 2012-12-21 | 2012-12-21 | |
US201361790525P | 2013-03-15 | 2013-03-15 | |
PCT/US2013/077235 WO2014100719A2 (en) | 2012-12-21 | 2013-12-20 | Prmt5 inhibitors and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1121625T1 true CY1121625T1 (el) | 2020-07-31 |
Family
ID=49958717
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20181101294T CY1121625T1 (el) | 2012-12-21 | 2018-12-05 | Αναστολεις prmt5 και χρησεις αυτων |
Country Status (30)
Country | Link |
---|---|
US (10) | US8993555B2 (el) |
EP (3) | EP3498701B1 (el) |
JP (1) | JP6678455B2 (el) |
KR (2) | KR102024417B1 (el) |
CN (1) | CN105452226B (el) |
AU (1) | AU2018202150B2 (el) |
BR (1) | BR112015014590B1 (el) |
CA (1) | CA2894228C (el) |
CL (1) | CL2015001790A1 (el) |
CR (1) | CR20150371A (el) |
CY (1) | CY1121625T1 (el) |
DK (1) | DK2935222T3 (el) |
DO (1) | DOP2015000158A (el) |
EA (1) | EA027908B1 (el) |
ES (1) | ES2701069T3 (el) |
HK (1) | HK1212690A1 (el) |
HR (1) | HRP20182037T1 (el) |
HU (1) | HUE040323T2 (el) |
IL (3) | IL239296B (el) |
LT (1) | LT2935222T (el) |
MX (1) | MX2015008052A (el) |
PE (1) | PE20151501A1 (el) |
PH (2) | PH12015501351A1 (el) |
PL (1) | PL2935222T3 (el) |
PT (1) | PT2935222T (el) |
RS (1) | RS58040B1 (el) |
SI (1) | SI2935222T1 (el) |
UA (1) | UA118548C2 (el) |
WO (1) | WO2014100719A2 (el) |
ZA (1) | ZA201505212B (el) |
Families Citing this family (112)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012170904A2 (en) * | 2011-06-10 | 2012-12-13 | Bytemobile, Inc. | Adaptive bitrate management on progressive download with indexed media files |
TWI568722B (zh) | 2012-06-15 | 2017-02-01 | 葛蘭馬克製藥公司 | 作爲mPGES-1抑制劑之三唑酮化合物 |
US9908887B2 (en) * | 2012-12-21 | 2018-03-06 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
RS61767B1 (sr) | 2012-12-21 | 2021-05-31 | Janssen Biopharma Inc | 4'-fluor-nukleozidi, 4'-fluor-nukleotidi i njihovi analozi za lečenje hcv |
US8993555B2 (en) | 2012-12-21 | 2015-03-31 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
US9365555B2 (en) | 2012-12-21 | 2016-06-14 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
JP2016505597A (ja) | 2012-12-21 | 2016-02-25 | エピザイム,インコーポレイティド | Prmt5阻害剤およびその使用 |
WO2014100730A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof |
UA111305C2 (uk) | 2012-12-21 | 2016-04-11 | Пфайзер Інк. | Конденсовані лактами арилу та гетероарилу |
US9278950B2 (en) | 2013-01-14 | 2016-03-08 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
EA035929B1 (ru) | 2013-01-15 | 2020-09-02 | Инсайт Холдингс Корпорейшн | ТИАЗОЛКАРБОКСАМИДЫ И ПИРИДИНКАРБОКСАМИДЫ, ИСПОЛЬЗУЕМЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Pim-КИНАЗЫ |
JP2016514164A (ja) | 2013-03-14 | 2016-05-19 | エピザイム,インコーポレイティド | アルギニンメチルトランスフェラーゼ阻害剤としてのピラゾール誘導体およびその使用 |
US9045455B2 (en) | 2013-03-14 | 2015-06-02 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
WO2014144659A1 (en) | 2013-03-14 | 2014-09-18 | Epizyme, Inc. | Pyrazole derivatives as prmt1 inhibitors and uses thereof |
US9447079B2 (en) | 2013-03-14 | 2016-09-20 | Epizyme, Inc. | PRMT1 inhibitors and uses thereof |
SI2970132T1 (sl) | 2013-03-14 | 2021-02-26 | Epizyme, Inc. | Inhibitorji argininmetiltransferaze in njihove uporabe |
US9120757B2 (en) | 2013-03-14 | 2015-09-01 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
US9394258B2 (en) | 2013-03-14 | 2016-07-19 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
WO2014153214A1 (en) | 2013-03-14 | 2014-09-25 | Epizyme, Inc. | Arginine methyl transferase inhibtors and uses thereof |
EA201591532A1 (ru) | 2013-03-15 | 2016-03-31 | Эпизим, Инк. | Ингибиторы carm1 и их применение |
US9346802B2 (en) | 2013-03-15 | 2016-05-24 | Epizyme, Inc. | CARM1 inhibitors and uses thereof |
WO2014144455A1 (en) | 2013-03-15 | 2014-09-18 | Epizyme, Inc. | 1 -phenoxy-3-(alkylamino)-propan-2-ol derivatives as carm1 inhibitors and uses thereof |
MX2016002367A (es) | 2013-08-23 | 2016-10-28 | Incyte Corp | Compuestos de carboxamida de furo y tienopiridina utiles como inhibidores de cinasas pim. |
PE20161552A1 (es) | 2014-06-17 | 2017-01-11 | Pfizer | Compuestos de dihidroisoquinolinona sustituida |
US20170198006A1 (en) * | 2014-06-25 | 2017-07-13 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
US20170210751A1 (en) * | 2014-06-25 | 2017-07-27 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
CR20160598A (es) * | 2014-06-25 | 2017-03-10 | Glaxosmithkline Intelectual Property Dev Ltd | Sales cristalinas de (s)-6-((1-acetilpiperidin-4-il) amino)-n-(3-(3,4-dihidroisoquinolin-2(1h)-il)-2-hidroxipropil) pirimidino-4-carboxamida |
US9822124B2 (en) | 2014-07-14 | 2017-11-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors |
US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
US10653693B2 (en) | 2014-08-04 | 2020-05-19 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
GB201415573D0 (en) * | 2014-09-03 | 2014-10-15 | Cancer Therapeutics Crc Pty Ltd | Compounds |
US10494376B2 (en) | 2014-09-03 | 2019-12-03 | Ctxt Pty. Ltd. | Tetrahydroisoquinoline derived PRMT5-inhibitors |
WO2016034671A1 (en) * | 2014-09-03 | 2016-03-10 | Ctxt Pty Ltd | Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived prmt5-inhibitors |
US20180010132A1 (en) | 2014-09-11 | 2018-01-11 | Novartis Ag | Inhibition of prmt5 to treat mtap-deficiency-related diseases |
EP3227446A1 (en) | 2014-12-01 | 2017-10-11 | Novartis AG | Compositions and methods for diagnosis and treatment of prostate cancer |
AR104326A1 (es) | 2015-05-04 | 2017-07-12 | Lilly Co Eli | Compuestos nucleósidos 5-sustituidos |
US9540347B2 (en) | 2015-05-29 | 2017-01-10 | Incyte Corporation | Pyridineamine compounds useful as Pim kinase inhibitors |
TWI791251B (zh) * | 2015-08-26 | 2023-02-01 | 比利時商健生藥品公司 | 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物 |
TWI734699B (zh) | 2015-09-09 | 2021-08-01 | 美商英塞特公司 | Pim激酶抑制劑之鹽 |
TW201718546A (zh) | 2015-10-02 | 2017-06-01 | 英塞特公司 | 適用作pim激酶抑制劑之雜環化合物 |
CN105497034B (zh) * | 2015-12-08 | 2018-08-07 | 暨南大学 | 一种通过靶向prmt5抑制骨肉瘤生长的组合物及其制备方法 |
GB201604031D0 (en) * | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
GB201604030D0 (en) * | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
GB201604029D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
GB201604027D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
GB201604020D0 (en) * | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
GB201604022D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
MX2018010923A (es) | 2016-03-10 | 2019-02-13 | Janssen Pharmaceutica Nv | Analogos de nucleosidos sustituidos para su uso como inhibidores de prmt5. |
CA3016096C (en) | 2016-03-10 | 2023-10-17 | Janssen Pharmaceutica Nv | Substituted nucleoside analogues for use as prmt5 inhibitors |
CA2969295A1 (en) * | 2016-06-06 | 2017-12-06 | Pfizer Inc. | Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor |
WO2018049214A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
AU2017326485B2 (en) | 2016-09-14 | 2021-04-22 | Janssen Pharmaceutica Nv | Fused bicyclic inhibitors of menin-MLL interaction |
US12084462B2 (en) | 2016-09-14 | 2024-09-10 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-MLL interaction |
MX2019002962A (es) | 2016-09-14 | 2019-07-04 | Janssen Pharmaceutica Nv | Inhibidores espirobiciclicos de la interaccion de menina-mll. |
TN2019000087A1 (en) | 2016-10-03 | 2020-07-15 | Janssen Pharmaceutica Nv | Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors |
WO2018065365A1 (en) | 2016-10-03 | 2018-04-12 | Janssen Pharmaceutica Nv | Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors |
KR20190084063A (ko) | 2016-10-28 | 2019-07-15 | 이칸 스쿨 오브 메디슨 엣 마운트 시나이 | Ezh2-매개성 암 치료용 조성물 및 방법 |
BR112019011350A2 (pt) * | 2016-12-01 | 2019-10-22 | Glaxosmithkline Ip Dev Ltd | terapia de combinação |
EP3548020A1 (en) * | 2016-12-01 | 2019-10-09 | GlaxoSmithKline Intellectual Property Development Limited | Combination therapy |
CN110267659A (zh) | 2016-12-08 | 2019-09-20 | 西奈山伊坎医学院 | 用于治疗cdk4/6介导的癌症的组合物和方法 |
MX2019007067A (es) | 2016-12-15 | 2019-10-15 | Janssen Pharmaceutica Nv | Inhibidores de azepano de la interacción menina-mll. |
JOP20190199B1 (ar) | 2017-02-27 | 2023-09-17 | Janssen Pharmaceutica Nv | استخدام العوامل الحيوية في تحديد مرضى السرطان الذين سوف يستجيبون للعلاج بمثبط prmt5 |
WO2018161922A1 (zh) * | 2017-03-09 | 2018-09-13 | 中国科学院上海药物研究所 | 一种具有prmt5抑制活性的化合物及其制备和应用 |
GB201704327D0 (en) * | 2017-03-17 | 2017-05-03 | Argonaut Therapeutics Ltd | Compounds |
EP3665179B1 (en) * | 2017-08-09 | 2021-06-09 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
WO2019058393A1 (en) | 2017-09-22 | 2019-03-28 | Jubilant Biosys Limited | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF PAD |
SG11202003463XA (en) | 2017-10-18 | 2020-05-28 | Jubilant Epipad LLC | Imidazo-pyridine compounds as pad inhibitors |
CN111386265A (zh) | 2017-11-06 | 2020-07-07 | 朱比连特普罗德尔有限责任公司 | 作为pd1/pd-l1活化的抑制剂的嘧啶衍生物 |
WO2019094311A1 (en) | 2017-11-08 | 2019-05-16 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
MX2020005363A (es) * | 2017-11-24 | 2020-10-01 | Jubilant Episcribe Llc | Compuestos heterociclicos como inhibidores de prmt5. |
BR112020010815A2 (pt) | 2017-12-08 | 2020-11-10 | Janssen Pharmaceutica Nv | análogos espirobicíclicos |
US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
IL274936B2 (en) | 2017-12-13 | 2023-09-01 | Lupin Ltd | Transmuted heterocyclic bicyclic compounds as prmt5 inhibitors |
US11396517B1 (en) | 2017-12-20 | 2022-07-26 | Janssen Pharmaceutica Nv | Exo-aza spiro inhibitors of menin-MLL interaction |
EP3755317A4 (en) * | 2018-02-22 | 2022-02-23 | Icahn School of Medicine at Mount Sinai | COMPOUNDS DEGRADING/DESTRUCTING PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) AND METHODS OF USE |
US11472799B2 (en) | 2018-03-06 | 2022-10-18 | Icahn School Of Medicine At Mount Sinai | Serine threonine kinase (AKT) degradation / disruption compounds and methods of use |
EP3761978A4 (en) * | 2018-03-09 | 2021-10-27 | Pharmablock Sciences (Nanjing), Inc. | INHIBITORS OF PROTEIN-ARGININE-METHYL TRANSFERASE 5 (PRMT5), PHARMACEUTICAL PRODUCTS THEREOF AND METHODS FOR THEREOF |
EP3765453A1 (en) | 2018-03-13 | 2021-01-20 | Jubilant Prodel LLC | Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation |
EP3768670A4 (en) * | 2018-03-22 | 2021-11-24 | Aurigene Discovery Technologies Limited | IMIDAZOLIDIN-2-ON COMPOUNDS AS PRMT5 MODULATORS |
KR20200135827A (ko) | 2018-03-22 | 2020-12-03 | 오리진 디스커버리 테크놀로지스 리미티드 | Prmt5 억제제로서 치환된 이미다졸리딘-2-온 유도체 |
WO2019219805A1 (en) | 2018-05-16 | 2019-11-21 | Ctxone Pty Ltd | Combination therapy |
US11077101B1 (en) | 2018-07-18 | 2021-08-03 | Tango Therapeutics, Inc. | Compounds and methods of use |
US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
BR112021007823A2 (pt) * | 2018-11-08 | 2021-07-27 | Glaxosmithkline Intellectual Property Development Limited | combinação de inibidores da prmt5 e inibidores do bcl-2 |
CN113330009B (zh) * | 2019-03-12 | 2024-02-09 | 四川科伦博泰生物医药股份有限公司 | 氮杂环化合物、其制备方法及用途 |
US20230212143A9 (en) * | 2019-03-29 | 2023-07-06 | University Of Florida Research Foundation, Incorporated | Prmt5 inhibitor compounds |
CN111825656B (zh) * | 2019-04-15 | 2023-03-31 | 南京药石科技股份有限公司 | 蛋白质精氨酸甲基转移酶5(prmt5)的抑制剂、其药学产品及其方法 |
TW202112375A (zh) | 2019-06-06 | 2021-04-01 | 比利時商健生藥品公司 | 使用prmt5抑制劑治療癌症之方法 |
RS64972B1 (sr) | 2019-06-10 | 2024-01-31 | Lupin Ltd | Inhibitori prmt5 |
WO2020249663A1 (en) | 2019-06-12 | 2020-12-17 | Janssen Pharmaceutica Nv | Novel spirobicyclic intermediates |
WO2020263550A1 (en) | 2019-06-28 | 2020-12-30 | Als Therapy Development Institute | Inhibition of dipeptide repeat proteins |
CN110585434B (zh) * | 2019-10-11 | 2021-04-09 | 山东大学 | Prmt5抑制剂在抗病毒中的应用 |
CN112645946B (zh) | 2019-10-12 | 2024-03-12 | 南京圣和药业股份有限公司 | 作为prmt5抑制剂的取代三环类化合物及其应用 |
GEP20247638B (en) | 2019-10-22 | 2024-07-10 | Lupin Ltd | Pharmaceutical combination of prmt5 inhibitors |
CN112778275B (zh) * | 2019-11-11 | 2023-05-12 | 石药集团中奇制药技术(石家庄)有限公司 | 金刚烷基prmt5抑制剂及其应用 |
CN110950841A (zh) * | 2019-11-22 | 2020-04-03 | 济南大学 | 一类新型三唑类化合物的合成及应用 |
CN111018832A (zh) * | 2019-11-26 | 2020-04-17 | 济南大学 | 一类含有四氢异喹啉结构的咪唑酮类化合物的制备及应用 |
EP4069698A1 (en) | 2019-12-03 | 2022-10-12 | Lupin Limited | Substituted nucleoside analogs as prmt5 inhibitors |
KR102514245B1 (ko) * | 2019-12-03 | 2023-03-29 | 한양대학교 에리카산학협력단 | 단백질 인산화 효소 저해 활성을 갖는 신규한 피라졸 유도체 및 이의 용도 |
WO2021126731A1 (en) | 2019-12-17 | 2021-06-24 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
EP4076459A4 (en) * | 2019-12-17 | 2023-12-20 | Merck Sharp & Dohme LLC | PRMT5 INHIBITORS |
CN113045543B (zh) * | 2019-12-26 | 2023-05-12 | 石药集团中奇制药技术(石家庄)有限公司 | 一种prmt5抑制剂及其应用 |
JP7507892B2 (ja) * | 2020-06-02 | 2024-06-28 | 石薬集団中奇制薬技術(石家庄)有限公司 | 3,4-ジヒドロイソキノリン系化合物及びその使用 |
CN113754541A (zh) * | 2020-06-02 | 2021-12-07 | 深圳湾实验室 | 靶向eb病毒核抗原蛋白的小分子抑制剂、制备方法及其应用 |
CN111592522B (zh) * | 2020-06-17 | 2022-09-09 | 郑州大学 | 一种精氨酸甲基化转移酶5小分子抑制剂及其制备方法和用途 |
CN116568677A (zh) | 2020-07-31 | 2023-08-08 | 探戈医药股份有限公司 | 可用于治疗mtap缺乏和/或mta累积癌症的哌啶-1-基-n-吡啶-3-基-2-氧代乙酰胺衍生物 |
WO2022048631A1 (zh) | 2020-09-04 | 2022-03-10 | 上海翊石医药科技有限公司 | 一种具有抗肿瘤活性的化合物及其用途 |
CN116134034A (zh) * | 2020-09-22 | 2023-05-16 | 南京明德新药研发有限公司 | 四氢异喹啉衍生物及其应用 |
CA3222626A1 (en) | 2021-05-13 | 2022-11-17 | Yunlong Song | Compound having anti-tumor activity and use thereof |
GB202117230D0 (en) | 2021-11-29 | 2022-01-12 | Argonaut Therapeutics Ltd | Peptide vaccine |
WO2023104107A1 (zh) * | 2021-12-08 | 2023-06-15 | 石药集团中奇制药技术(石家庄)有限公司 | 3,4-二氢异喹啉类化合物的盐及其应用 |
GB202203588D0 (en) | 2022-03-15 | 2022-04-27 | Argonaut Therapeutics Ltd | Cancer diagnostic |
Family Cites Families (183)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DD68906A (el) | ||||
DE63776C (de) | A. RUPERT, Eisenbahn - Werkmeister, in Köln - Nippes, Escherstrafse 14 | Verfahren und Vorrichtung eiserne Rohrwände mit Messing zu überziehen | ||
GB1374366A (en) | 1972-07-21 | 1974-11-20 | Science Union & Cie | Propanol derivatives and a process for their preparation |
DE2361390A1 (de) * | 1973-12-10 | 1975-06-19 | Merck Patent Gmbh | Isochinolinderivate und verfahren zu ihrer herstellung |
US4026897A (en) | 1974-01-31 | 1977-05-31 | Otsuka Pharmaceutical Company | 5-[1-Hydroxy-2-(substituted-amino)]alkyl-8-hydroxycarbostyril derivatives |
CA1072359A (en) | 1974-10-08 | 1980-02-26 | Hiroyuki Konishi | Method for controlling the growth of plants |
HU179951B (en) | 1979-10-11 | 1983-01-28 | Chinoin Gyogyszer Es Vegyeszet | Process for preparing 1,2,4-oxadiazolin-5-one derivatives and pharmaceutical compositions containing thereof |
US4270537A (en) | 1979-11-19 | 1981-06-02 | Romaine Richard A | Automatic hypodermic syringe |
IL68996A0 (en) | 1982-06-16 | 1983-10-31 | May & Baker Ltd | New pyrazolopyridine derivative |
DE3303344A1 (de) | 1983-02-02 | 1984-08-02 | Hoechst Ag, 6230 Frankfurt | Verfahren zur herstellung von n-alkylierten aminosaeuren und deren estern |
US4684459A (en) | 1985-11-29 | 1987-08-04 | The Dow Chemical Company | Collector compositions for the froth flotation of mineral values |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
JPH07100688B2 (ja) * | 1986-02-12 | 1995-11-01 | 大日本製薬株式会社 | 環状アミン誘導体 |
DE3631013A1 (de) * | 1986-09-12 | 1988-03-24 | Thomae Gmbh Dr K | Neue naphthylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
DE3640641A1 (de) | 1986-11-28 | 1988-07-14 | Thomae Gmbh Dr K | Neue heteroaromatische aminderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
CA1283827C (en) | 1986-12-18 | 1991-05-07 | Giorgio Cirelli | Appliance for injection of liquid formulations |
GB8704027D0 (en) | 1987-02-20 | 1987-03-25 | Owen Mumford Ltd | Syringe needle combination |
US4746655A (en) | 1987-06-10 | 1988-05-24 | A. H. Robins Company, Incorporated | Fused aromatic-spiropiperidine oxazepinones(and thiones) |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US4940460A (en) | 1987-06-19 | 1990-07-10 | Bioject, Inc. | Patient-fillable and non-invasive hypodermic injection device assembly |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
DE3804793A1 (de) | 1988-02-16 | 1989-08-24 | Hoechst Ag | Renin-hemmende aminosaeurederivate |
US5339163A (en) | 1988-03-16 | 1994-08-16 | Canon Kabushiki Kaisha | Automatic exposure control device using plural image plane detection areas |
FR2638359A1 (fr) | 1988-11-03 | 1990-05-04 | Tino Dalto | Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau |
DE3839126A1 (de) | 1988-11-19 | 1990-05-23 | Hoechst Ag | Renin-hemmende harnstoffderivate von dipeptiden, verfahren zu deren herstellung, diese enthaltende mittel und ihre verwendung |
US5776963A (en) | 1989-05-19 | 1998-07-07 | Hoechst Marion Roussel, Inc. | 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
GB9005318D0 (en) | 1990-03-09 | 1990-05-02 | Isis Innovation | Antiarrhythmic agents |
US5190521A (en) * | 1990-08-22 | 1993-03-02 | Tecnol Medical Products, Inc. | Apparatus and method for raising a skin wheal and anesthetizing skin |
US5527288A (en) | 1990-12-13 | 1996-06-18 | Elan Medical Technologies Limited | Intradermal drug delivery device and method for intradermal delivery of drugs |
WO1993001174A1 (en) | 1991-07-08 | 1993-01-21 | Glaxo Group Limited | Thiazolidine derivatives and their use as anti-viral compounds |
GB9118204D0 (en) | 1991-08-23 | 1991-10-09 | Weston Terence E | Needle-less injector |
SE9102652D0 (sv) | 1991-09-13 | 1991-09-13 | Kabi Pharmacia Ab | Injection needle arrangement |
US5328483A (en) | 1992-02-27 | 1994-07-12 | Jacoby Richard M | Intradermal injection device with medication and needle guard |
EP0649410B1 (en) | 1992-07-10 | 1997-05-02 | Laboratoires Glaxo Sa | Anilide derivatives |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
US5514694A (en) | 1992-09-21 | 1996-05-07 | Georgia Tech Research Corp | Peptidyl ketoamides |
US5569189A (en) | 1992-09-28 | 1996-10-29 | Equidyne Systems, Inc. | hypodermic jet injector |
US5294621A (en) | 1992-10-07 | 1994-03-15 | Ortho Pharmaceutical Corporation | Thieno tetrahydropyridines useful as class III antiarrhythmic agents |
US5334144A (en) | 1992-10-30 | 1994-08-02 | Becton, Dickinson And Company | Single use disposable needleless injector |
GB9402807D0 (en) * | 1994-02-14 | 1994-04-06 | Xenova Ltd | Pharmaceutical compounds |
WO1995024176A1 (en) | 1994-03-07 | 1995-09-14 | Bioject, Inc. | Ampule filling device |
US5466220A (en) | 1994-03-08 | 1995-11-14 | Bioject, Inc. | Drug vial mixing and transfer device |
US5599302A (en) | 1995-01-09 | 1997-02-04 | Medi-Ject Corporation | Medical injection system and method, gas spring thereof and launching device using gas spring |
US5693847A (en) | 1995-04-19 | 1997-12-02 | Vertex Pharmaceuticals Incorporated | Heteroatom functionalized α-methyl ketones |
US5730723A (en) * | 1995-10-10 | 1998-03-24 | Visionary Medical Products Corporation, Inc. | Gas pressured needle-less injection device and method |
US5554621A (en) * | 1995-06-07 | 1996-09-10 | Bristol-Myers Squibb Company | Dihydropyridine NPY antagonists: nitrogen heterocyclic derivatives |
US6130217A (en) | 1995-09-20 | 2000-10-10 | Pfizer Inc | Compounds enhancing antitumor activity of other cytotoxic agents |
US5893397A (en) | 1996-01-12 | 1999-04-13 | Bioject Inc. | Medication vial/syringe liquid-transfer apparatus |
SE9600769D0 (sv) | 1996-02-28 | 1996-02-28 | Astra Ab | Compounds useful as analgesic |
GB9607549D0 (en) | 1996-04-11 | 1996-06-12 | Weston Medical Ltd | Spring-powered dispensing device |
GB9717576D0 (en) * | 1997-08-19 | 1997-10-22 | Xenova Ltd | Pharmaceutical compounds |
US5874449A (en) | 1996-12-31 | 1999-02-23 | Gpi Nil Holdings, Inc. | N-linked sulfonamides of heterocyclic thioesters |
US5993412A (en) | 1997-05-19 | 1999-11-30 | Bioject, Inc. | Injection apparatus |
IT1298087B1 (it) | 1998-01-08 | 1999-12-20 | Fiderm S R L | Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni |
US20020169101A1 (en) | 1999-05-10 | 2002-11-14 | Gonzalez Maria Isabel | Treatment of sexual dysfunction |
EP1181291A2 (en) * | 1999-05-25 | 2002-02-27 | The Penn State Research Foundation | Dna methyltransferase inhibitors |
US7253165B2 (en) | 1999-09-14 | 2007-08-07 | Aventis Pharmaceuticals Inc. | Benzisoxazolyl-, pyridoisoxazolyl-and benzthienyl-phenoxy derivatives useful as D4 antagonists |
US7125903B1 (en) | 1999-09-14 | 2006-10-24 | Aventis Pharmaceuticals Inc. | Thienoisoxazolyl-and thienylpyrrazolyl-phenoxy substituted propyl derivatives useful as D4 antagonists |
MXPA02002695A (es) | 1999-09-14 | 2002-07-30 | Aventis Pharm Prod Inc | Derivados de propilo tienoisoxazolil- y tienilpirrazolil-fenoxi sustituidos utiles como antagonistas de d4. |
AU7479400A (en) | 1999-09-14 | 2001-04-17 | Aventis Pharmaceuticals Inc. | Benzisoxazolyl-, pyridoisoxazolyl- and benzthienyl-phenoxy derivatives useful as d4 antagonists |
BRPI0109200B8 (pt) | 2000-03-14 | 2021-05-25 | Actelion Pharmaceuticals Ltd | compostos e composições farmacêuticas |
AU2001277728A1 (en) | 2000-08-10 | 2002-02-25 | Tanabe Seiyaku Co., Ltd. | Biphenylcarboxamidoisoindoline compounds, processes for the preparation of the same and intermediates for the synthesis thereof |
NZ527276A (en) * | 2001-03-27 | 2004-11-26 | Actelion Pharmaceuticals Ltd | 1,2,3,4-tetrahydroisoquinoline derivatives as urotensin II receptor antagonists |
AP2004002952A0 (en) | 2001-07-11 | 2004-03-31 | Elan Pharm Inc | N-(3-amino-2-hydroxy-propyl) substituted alkylamide compounds. |
WO2003018017A1 (en) | 2001-08-27 | 2003-03-06 | Arpida Ag | 3-substituted 6,7-dihydroxytetrahydroisoquinoline derivatives for use as antibacterial agents |
TWI259081B (en) | 2001-10-26 | 2006-08-01 | Sugen Inc | Treatment of acute myeloid leukemia with indolinone compounds |
SE0103644D0 (sv) | 2001-11-01 | 2001-11-01 | Astrazeneca Ab | Therapeutic isoquinoline compounds |
AR039555A1 (es) | 2001-11-08 | 2005-02-23 | Upjohn Co | Derivados n,n'-sustituidos de 1,3-diamino-2-hidroxipropano |
US7338969B2 (en) | 2002-03-08 | 2008-03-04 | Quonova, Llc | Modulation of pathogenicity |
US7335779B2 (en) | 2002-03-08 | 2008-02-26 | Quonova, Llc | Modulation of pathogenicity |
US7423067B2 (en) | 2002-03-26 | 2008-09-09 | Merck & Co., Inc. | Diphenyl cyclopentyl amides as cannabinoid-1 receptor inverse agonists |
US20050154202A1 (en) | 2002-04-05 | 2005-07-14 | Hagmann William K. | Substituted aryl amides |
US8013014B2 (en) | 2002-07-05 | 2011-09-06 | Georgia Tech Research Corporation | Aza-peptide epoxides |
EP1601674B1 (en) | 2002-09-09 | 2012-08-08 | Janssen Pharmaceutica NV | Hydroxyalkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders |
SE0300010D0 (sv) | 2003-01-07 | 2003-01-07 | Astrazeneca Ab | Novel Compounds |
AU2004218456A1 (en) | 2003-02-28 | 2004-09-16 | Encysive Pharmaceuticals Inc. | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists. |
WO2004078731A1 (fr) * | 2003-03-06 | 2004-09-16 | 'chemical Diversity Research Institute', Ltd. | Acides quinoline-carboxyliques et leurs derives et bibliotheque focalisee |
US7408008B2 (en) | 2003-12-09 | 2008-08-05 | Janssen Pharmaceutica, N.V. | Method of producing highly functionalized 1,3-diamino-propan-2-ols from solid support |
WO2005085227A1 (en) | 2004-03-02 | 2005-09-15 | Smithkline Beecham Corporation | Inhibitors of akt activity |
JP2007528402A (ja) | 2004-03-09 | 2007-10-11 | エラン ファーマシューティカルズ,インコーポレイテッド | 置換ヒドロキシエチルアミン系のアスパラギン酸プロテアーゼ阻害薬 |
RU2266906C1 (ru) * | 2004-04-29 | 2005-12-27 | Общество с ограниченной ответственностью "Исследовательский Институт Химического Разнообразия" (ООО "Исследовательский Институт Химического Разнообразия") | Анелированные карбамоилазагетероциклы, способы их получения (варианты), фармацевтическая композиция, фокусированная библиотека |
WO2005118543A1 (ja) | 2004-06-03 | 2005-12-15 | Ono Pharmaceutical Co., Ltd. | キナーゼ阻害薬およびその用途 |
EA200700117A1 (ru) | 2004-06-24 | 2007-06-29 | Инсайт Корпорейшн | N-замещенные пиперидины и их применение в качестве фармацевтических препаратов |
US20060009510A1 (en) | 2004-07-09 | 2006-01-12 | Pharmacia & Upjohn Company Llc | Method of synthesizing indolinone compounds |
JP2008007405A (ja) * | 2004-12-07 | 2008-01-17 | Takeda Chem Ind Ltd | カルボキサミド誘導体 |
US20100190788A1 (en) | 2005-07-11 | 2010-07-29 | Olivier Defert | Amide derivatives as kinase inhitors |
EP1910317B1 (en) | 2005-07-20 | 2013-07-03 | Eli Lilly And Company | 1-amino linked compounds |
GB0516723D0 (en) | 2005-08-15 | 2005-09-21 | Novartis Ag | Organic compounds |
EP1947943A4 (en) | 2005-10-21 | 2009-11-25 | Univ Alabama | SMALL MOLECULAR INHIBITORS OF HIV-1 CAPSIDE FORMATION |
CA2644069A1 (en) | 2006-02-28 | 2007-09-07 | Helicon Therapeutics, Inc. | Therapeutic piperazines as pde4 inhibitors |
DK2001474T3 (en) | 2006-03-16 | 2016-05-09 | Second Genome Inc | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND APPLICATIONS THEREOF |
JP2009536028A (ja) | 2006-05-05 | 2009-10-08 | ケンブリッジ エンタープライズ リミテッド | 遺伝子発現制御用のエピジェネティック調節複合体 |
EP2089023A2 (en) | 2006-11-02 | 2009-08-19 | Aestus Therapeutics, Inc. | Methods of treating neuropathic pain with agonists of ppar-gamma |
CN101012223A (zh) | 2006-11-13 | 2007-08-08 | 西安新安医药科技有限公司 | 用于治疗的奥硝唑衍生物、制备方法及用途 |
WO2008067756A1 (fr) | 2006-12-04 | 2008-06-12 | Jiangsu Simcere Pharmaceutical R & D Co., Ltd. | Dérivés de 3-pyrrolo-cyclohexylène-2-dihydro-indolinone et utilisations de ceux-ci |
CN101157929B (zh) * | 2007-02-02 | 2012-05-23 | 中国科学院上海有机化学研究所 | 番红霉素的生物合成基因簇 |
US20090099157A1 (en) | 2007-02-15 | 2009-04-16 | Ameriks Michael K | Tetrahydro-pyrazolo-pyridine thioether modulators of cathepsin s |
US8338437B2 (en) | 2007-02-28 | 2012-12-25 | Methylgene Inc. | Amines as small molecule inhibitors |
WO2008123582A1 (ja) * | 2007-04-04 | 2008-10-16 | Kowa Company, Ltd. | テトラヒドロイソキノリン化合物 |
DE102007020492A1 (de) | 2007-04-30 | 2008-11-06 | Grünenthal GmbH | Substituierte Sulfonamid-Derivate |
WO2008145398A1 (en) | 2007-06-01 | 2008-12-04 | Pfizer Italia S.R.L. | 4-arylpyrrole substituted 2-indoline derivatives active as protein kinase inhibitors |
EP2150626B1 (en) | 2007-06-07 | 2015-09-30 | Haplomic Technologies Pty Ltd. | Epigenetic methods |
US20090227533A1 (en) | 2007-06-08 | 2009-09-10 | Bader Andreas G | miR-34 Regulated Genes and Pathways as Targets for Therapeutic Intervention |
EP2014651A1 (en) | 2007-07-12 | 2009-01-14 | Exonhit Therapeutics SA | Compounds and methods for modulating Rho GTPases |
RU2345996C1 (ru) * | 2007-07-17 | 2009-02-10 | Андрей Александрович Иващенко | Аннелированные азагетероциклические амиды, включающие пиримидиновый фрагмент, способ их получения и применения |
NZ562237A (en) | 2007-10-05 | 2011-02-25 | Pacific Edge Biotechnology Ltd | Proliferation signature and prognosis for gastrointestinal cancer |
US20090093493A1 (en) | 2007-10-09 | 2009-04-09 | Francesco Berardi | 1-phenylalcoxy-2-beta-phenylethyl derivatives as p-glycoprotein (p-gp) inhibitors useful in drug resistance events |
AR070950A1 (es) | 2007-11-01 | 2010-05-19 | Acucela Inc | Compuestos derivados de amina, composiciones farmaceuticas de ellos, compuestos inhibidores de produccion de 11-cis-retinol y metodos para tratar enfermedades y trastornos oftalmicos |
US8722851B2 (en) | 2007-11-02 | 2014-05-13 | Pain Therapeutics, Inc. | Analgesia with minimal tolerance and dependence by a mu opioid receptor agonist that also binds filamin A |
EP2219646A4 (en) | 2007-12-21 | 2010-12-22 | Univ Rochester | METHOD FOR MODIFYING THE LIFETIME OF EUKARYOTIC ORGANISMS |
RU2371444C1 (ru) * | 2008-01-24 | 2009-10-27 | Андрей Александрович Иващенко | ФУРО- И ТИЕНО[2,3-b]-ХИНОЛИН-2-КАРБОКСАМИДЫ, СПОСОБ ПОЛУЧЕНИЯ И ПРОТИВОТУБЕРКУЛЕЗНАЯ АКТИВНОСТЬ |
WO2009126782A1 (en) | 2008-04-11 | 2009-10-15 | High Point Pharmaceuticals, Llc | Histamine h3 receptor ligands |
EP2307345A4 (en) | 2008-07-01 | 2012-05-02 | Purdue Research Foundation | NON-PEPTIDINHIBITORS OF HIV-1 PROTEASE |
FR2933977B1 (fr) * | 2008-07-18 | 2013-04-26 | Centre Nat Rech Scient | Derives heterocycliques utiles dans le traitement des maladies neurodegeneratives |
EP2344451A4 (en) | 2008-09-05 | 2014-08-13 | Acucela Inc | SULFUR-BINDING COMPONENTS FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS |
KR101546562B1 (ko) | 2008-10-22 | 2015-08-25 | 어큐셀라 인코포레이티드 | 안과 질환 및 장애 치료용 화합물 |
WO2010057101A2 (en) | 2008-11-17 | 2010-05-20 | Schering Corporation | Compounds useful as hiv blockers |
BRPI1014125A2 (pt) | 2009-03-17 | 2016-04-12 | Daiichi Sankyo Co Ltd | composto, composição farmacêutica, e, uso de um composto. |
US8309547B2 (en) | 2009-04-28 | 2012-11-13 | Apotex Pharmachem Inc. | Processes for the preparation of rivaroxaban and intermediates thereof |
AU2010258800B2 (en) | 2009-06-09 | 2013-10-10 | Nantbio, Inc. | Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling |
EP2453908B1 (en) | 2009-07-13 | 2018-03-14 | President and Fellows of Harvard College | Bifunctional stapled polypeptides and uses thereof |
GB0922332D0 (en) | 2009-12-22 | 2010-02-03 | Isis Innovation | Method of treatment and screening method |
US9044432B2 (en) * | 2009-12-22 | 2015-06-02 | Ohio State Innovation Foundation | Compositions and methods for cancer detection and treatment |
EP2357176A1 (en) * | 2010-01-15 | 2011-08-17 | Hybrigenics S.A. | Amidoacridine derivatives useful as selective inhibitors of ubiquitin specific protease 7 |
US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
TWI513694B (zh) | 2010-05-11 | 2015-12-21 | Amgen Inc | 抑制間變性淋巴瘤激酶的嘧啶化合物 |
JOP20190250A1 (ar) | 2010-07-14 | 2017-06-16 | Regeneron Pharma | صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب |
WO2012051692A1 (en) | 2010-10-18 | 2012-04-26 | Apotex Pharmachem Inc. | Processes for the preparation of rivaroxaban and intermediates thereof |
EP2630232A4 (en) | 2010-10-22 | 2014-04-02 | Biotime Inc | METHOD FOR MODIFYING TRANSCRIPTIONAL REGULATORY NETWORKS IN STEM CELLS |
EP2646455A4 (en) | 2010-12-03 | 2014-04-02 | Epizyme Inc | MODULATORS OF HISTON METHYLTRANSFERASE AND METHOD OF USE THEREOF |
CN103339139A (zh) | 2010-12-03 | 2013-10-02 | Epizyme股份有限公司 | 组蛋白甲基转移酶的7-氮杂嘌呤调节剂及其使用方法 |
DE12710995T1 (de) | 2011-03-25 | 2014-04-03 | Almac Sciences (Scotland) Ltd. | Enzymtests |
JP6363502B2 (ja) | 2011-04-28 | 2018-07-25 | スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ | Hsp90併用療法 |
EP3208615B1 (en) | 2011-07-08 | 2019-10-09 | Sloan Kettering Institute For Cancer Research | Uses of labeled hsp90 inhibitors |
WO2013038378A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
WO2013038381A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine/pyrazine amide derivatives |
EP3323897A1 (en) | 2011-10-03 | 2018-05-23 | Celmatix, Inc. | Methods and devices for assessing risk to a putative offspring of developing a condition |
TWI577671B (zh) | 2011-11-14 | 2017-04-11 | Sunshine Lake Pharma Co Ltd | Aminoquinazoline derivatives and salts thereof and methods of use thereof |
CA2860022A1 (fr) | 2011-12-30 | 2013-07-04 | Universite D'auvergne Clermont I | Composes anti-douleur |
WO2013150303A1 (en) | 2012-04-03 | 2013-10-10 | Reneuron Limited | Stem cell microparticles |
EP2872899B1 (en) | 2012-07-13 | 2018-07-11 | Pain Therapeutics, Inc. | Alzheimer's disease assay in a living patient |
AU2013291761B2 (en) | 2012-07-19 | 2018-03-15 | Reneuron Limited | Stem cell microparticles |
US9585891B2 (en) | 2012-09-25 | 2017-03-07 | Merck Patent Gmbh | Alpha hydroxy amides |
HUE046790T2 (hu) | 2012-10-15 | 2020-03-30 | Epizyme Inc | A rák kezelésének módszerei |
CA2886650A1 (en) | 2012-11-29 | 2014-06-05 | The Penn State Research Foundation | Photodynamic dhsip anticancer therapeutic and immunomodulator |
US8993555B2 (en) | 2012-12-21 | 2015-03-31 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
WO2014100730A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof |
US20150344457A1 (en) | 2012-12-21 | 2015-12-03 | Epizyme, Inc. | Methods of inhibiting prmt5 |
JP2016505597A (ja) | 2012-12-21 | 2016-02-25 | エピザイム,インコーポレイティド | Prmt5阻害剤およびその使用 |
US9365555B2 (en) | 2012-12-21 | 2016-06-14 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
US9908887B2 (en) | 2012-12-21 | 2018-03-06 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
US9045455B2 (en) | 2013-03-14 | 2015-06-02 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
US9394258B2 (en) | 2013-03-14 | 2016-07-19 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
US9120757B2 (en) | 2013-03-14 | 2015-09-01 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
WO2014153214A1 (en) | 2013-03-14 | 2014-09-25 | Epizyme, Inc. | Arginine methyl transferase inhibtors and uses thereof |
US9447079B2 (en) | 2013-03-14 | 2016-09-20 | Epizyme, Inc. | PRMT1 inhibitors and uses thereof |
US9365527B2 (en) | 2013-03-14 | 2016-06-14 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
WO2014144659A1 (en) | 2013-03-14 | 2014-09-18 | Epizyme, Inc. | Pyrazole derivatives as prmt1 inhibitors and uses thereof |
JP2016514164A (ja) | 2013-03-14 | 2016-05-19 | エピザイム,インコーポレイティド | アルギニンメチルトランスフェラーゼ阻害剤としてのピラゾール誘導体およびその使用 |
JP2016518336A (ja) | 2013-03-14 | 2016-06-23 | エピザイム,インコーポレイティド | Prmt1阻害剤としてのピラゾール誘導体およびその使用 |
SI2970132T1 (sl) | 2013-03-14 | 2021-02-26 | Epizyme, Inc. | Inhibitorji argininmetiltransferaze in njihove uporabe |
EA201591532A1 (ru) | 2013-03-15 | 2016-03-31 | Эпизим, Инк. | Ингибиторы carm1 и их применение |
US9346802B2 (en) | 2013-03-15 | 2016-05-24 | Epizyme, Inc. | CARM1 inhibitors and uses thereof |
WO2014144455A1 (en) | 2013-03-15 | 2014-09-18 | Epizyme, Inc. | 1 -phenoxy-3-(alkylamino)-propan-2-ol derivatives as carm1 inhibitors and uses thereof |
JP6113354B2 (ja) | 2013-05-03 | 2017-04-12 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 神経新生刺激イソキノリン誘導体 |
US20170198006A1 (en) | 2014-06-25 | 2017-07-13 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
US20170210751A1 (en) | 2014-06-25 | 2017-07-27 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
CR20160598A (es) | 2014-06-25 | 2017-03-10 | Glaxosmithkline Intelectual Property Dev Ltd | Sales cristalinas de (s)-6-((1-acetilpiperidin-4-il) amino)-n-(3-(3,4-dihidroisoquinolin-2(1h)-il)-2-hidroxipropil) pirimidino-4-carboxamida |
US10653693B2 (en) | 2014-08-04 | 2020-05-19 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
WO2016044626A1 (en) | 2014-09-17 | 2016-03-24 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
WO2016044585A1 (en) | 2014-09-17 | 2016-03-24 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
WO2016044556A2 (en) | 2014-09-17 | 2016-03-24 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
EP3194398A4 (en) | 2014-09-17 | 2018-02-21 | Epizyme, Inc. | Salts, co-crystals, amorphous forms, and crystalline forms of a co-activator-associated arginine methyltransferase 1 (carm1) inhibitor |
EP3193608A4 (en) | 2014-09-17 | 2018-05-02 | Epizyme, Inc. | Carm1 inhibitors and uses thereof |
WO2016044576A1 (en) | 2014-09-17 | 2016-03-24 | Epizyme, Inc. | Salts, co-crystals, amorphous forms, and crystalline forms of an arginine methyltransferase inhibitor |
WO2016044641A2 (en) | 2014-09-17 | 2016-03-24 | Epizyme, Inc. | Carm1 inhibitors and uses thereof |
US20170283440A1 (en) | 2014-09-17 | 2017-10-05 | Epizyme, Inc. | Carm1 inhibitors and uses thereof |
AU2016217874A1 (en) | 2015-02-11 | 2017-08-10 | Basilea Pharmaceutica International AG | Substituted mono- and polyazanaphthalene derivatives and their use |
WO2017136699A1 (en) | 2016-02-05 | 2017-08-10 | Epizyme, Inc | Arginine methyltransferase inhibitors and uses thereof |
AR108326A1 (es) | 2016-04-27 | 2018-08-08 | Samumed Llc | Isoquinolin-3-il carboxamidas y preparación y uso de las mismas |
GB201704476D0 (en) | 2017-03-21 | 2017-05-03 | Antabio Sas | Chemical compounds |
-
2013
- 2013-12-20 US US14/136,569 patent/US8993555B2/en active Active
- 2013-12-20 DK DK13821599.1T patent/DK2935222T3/en active
- 2013-12-20 US US14/654,253 patent/US9604930B2/en active Active
- 2013-12-20 SI SI201331283T patent/SI2935222T1/sl unknown
- 2013-12-20 CA CA2894228A patent/CA2894228C/en active Active
- 2013-12-20 ES ES13821599T patent/ES2701069T3/es active Active
- 2013-12-20 KR KR1020157019530A patent/KR102024417B1/ko active IP Right Grant
- 2013-12-20 WO PCT/US2013/077235 patent/WO2014100719A2/en active Application Filing
- 2013-12-20 JP JP2015549821A patent/JP6678455B2/ja active Active
- 2013-12-20 EP EP18192271.7A patent/EP3498701B1/en active Active
- 2013-12-20 PE PE2015001047A patent/PE20151501A1/es unknown
- 2013-12-20 KR KR1020197027023A patent/KR102173874B1/ko active IP Right Grant
- 2013-12-20 PL PL13821599T patent/PL2935222T3/pl unknown
- 2013-12-20 LT LTEP13821599.1T patent/LT2935222T/lt unknown
- 2013-12-20 EP EP13821599.1A patent/EP2935222B1/en active Active
- 2013-12-20 PT PT13821599T patent/PT2935222T/pt unknown
- 2013-12-20 RS RS20181485A patent/RS58040B1/sr unknown
- 2013-12-20 EA EA201590975A patent/EA027908B1/ru unknown
- 2013-12-20 BR BR112015014590-6A patent/BR112015014590B1/pt active IP Right Grant
- 2013-12-20 HU HUE13821599A patent/HUE040323T2/hu unknown
- 2013-12-20 MX MX2015008052A patent/MX2015008052A/es active IP Right Grant
- 2013-12-20 EP EP23156656.3A patent/EP4219465A3/en active Pending
- 2013-12-20 CN CN201380070441.2A patent/CN105452226B/zh active Active
- 2013-12-20 UA UAA201505700A patent/UA118548C2/uk unknown
-
2015
- 2015-02-11 US US14/619,371 patent/US9365519B2/en active Active
- 2015-06-09 IL IL239296A patent/IL239296B/en active IP Right Grant
- 2015-06-15 PH PH12015501351A patent/PH12015501351A1/en unknown
- 2015-06-19 CL CL2015001790A patent/CL2015001790A1/es unknown
- 2015-06-19 DO DO2015000158A patent/DOP2015000158A/es unknown
- 2015-07-13 CR CR20150371A patent/CR20150371A/es unknown
- 2015-07-20 ZA ZA2015/05212A patent/ZA201505212B/en unknown
-
2016
- 2016-01-20 HK HK16100586.2A patent/HK1212690A1/zh unknown
- 2016-02-26 US US15/054,193 patent/US9675614B2/en active Active
-
2017
- 2017-01-30 US US15/419,260 patent/US10307413B2/en active Active
- 2017-05-04 US US15/586,775 patent/US20180098987A1/en not_active Abandoned
- 2017-12-15 US US15/844,097 patent/US10391089B2/en active Active
-
2018
- 2018-03-26 AU AU2018202150A patent/AU2018202150B2/en active Active
- 2018-07-30 IL IL260876A patent/IL260876B/en active IP Right Grant
- 2018-12-04 HR HRP20182037TT patent/HRP20182037T1/hr unknown
- 2018-12-05 CY CY20181101294T patent/CY1121625T1/el unknown
-
2019
- 2019-01-23 PH PH12019500163A patent/PH12019500163A1/en unknown
- 2019-04-26 US US16/395,844 patent/US20190343826A1/en not_active Abandoned
- 2019-06-16 IL IL267364A patent/IL267364A/en unknown
- 2019-07-08 US US16/504,910 patent/US10980794B2/en active Active
-
2021
- 2021-03-02 US US17/189,989 patent/US20210308121A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1121625T1 (el) | Αναστολεις prmt5 και χρησεις αυτων | |
CY1123637T1 (el) | Αναστολεις μεθυλοτρανσφερασης αργινινης και χρησεις αυτων | |
CY1121418T1 (el) | Παρεμποδιστες ιου ηπατιτιδας c | |
CY1123756T1 (el) | Παραγωγα διπυραζολιου ως αναστολεις jak | |
CY1122601T1 (el) | Αναστολεις gsk3 και μεθοδοι χρησης αυτων | |
CY1123810T1 (el) | Τριφθορομεθυλ υποκατεστημενα πυραζολια ως αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα | |
EA201590224A1 (ru) | Имидазотриазинкарбонитрилы, используемые в качестве ингибиторов киназы | |
WO2015200680A8 (en) | Prmt5 inhibitors and uses thereof | |
WO2014153100A3 (en) | Arginine methyltransferase inhibitors and uses thereof | |
WO2014153235A3 (en) | Arginine methyltransferase inhibitors and uses thereof | |
CY1118662T1 (el) | Νεες δικυκλικες πυριδινονες | |
CY1120378T1 (el) | Υποκατεστημενα παραγωγα του διφαινυλο βουτανοϊκου φωσφονικου οξεος ως αναστολεις νερ (ουδετερης ενδοπεπτιδασης) | |
EA201500298A1 (ru) | Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы | |
EA201500628A1 (ru) | Индолкарбоксамидные производные в качестве антагонистов p2xрецепторов | |
CO7131360A2 (es) | Novedosas n-piridinil amidas cíclicas sustituidas como inhibidores de quinasa | |
EA201291217A1 (ru) | ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ 1-(β-D-ГЛЮКОПИРАНОЗИЛ)-2-ТИЕНИЛМЕТИЛБЕНЗОЛА КАК ИНГИБИТОРЫ НЗПГ | |
EA201490471A1 (ru) | Пиридазиноновые соединения и их применение в качестве ингибиторов daao | |
PH12016501462A1 (en) | Neprilysin inhibitors | |
CY1124251T1 (el) | Παραγωγα καρβοξαμιδιου | |
CY1120133T1 (el) | Πυριδαζινονες ως αναστολεις ενζυμου daao | |
EA201500931A1 (ru) | Производные пиридин-4-ила | |
GB201209587D0 (en) | Therapeutic compounds | |
EA201690390A1 (ru) | Производные амидов в качестве антагонистов рецептора к лизофосфатидной кислоте | |
EA201491227A1 (ru) | Новые производные морфолинила, подходящие для применения в качестве ингибиторов mogat-2 | |
EA201590656A1 (ru) | Азаиндолины |